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Abstract: Recently, we showed that platelet phagocytosis occurs in
human atherosclerotic plaques and leads to foam cell formation.
Platelet phagocytosis, resulting in macrophage activation and iNOS
induction, was associated with the formation of amyloid- peptide
(A) via proteolytic cleavage of platelet-derived amyloid precursor
protein (APP), possibly by secretases. To test the involvement of
-secretase in this process, we used indomethacin, ibuprofen, and su-
lindac sulfide, non-steroidal anti-inflammatory drugs (NSAIDs)
known to alter the -secretase cleaving site of APP, on their ability to
inhibit macrophage activation evoked by platelet phagocytosis. J774
macrophages were incubated with human platelets or lipopolysaccha-
ride (LPS) with or without NSAIDs. Nitrite was quantified as a mea-
sure for inducible nitric oxide synthase (iNOS) activity. Indometha-
cin, ibuprofen, sulindac sulfide, and meloxicam concentration-
dependently reduced nitrite production by macrophages incubated
with platelets, but did not alter LPS-induced iNOS activity or platelet
uptake. However, acetylsalicylic acid and naproxen, two NSAIDs
without effect on the -secretase cleaving site of APP, did not affect
nitrite production in either platelet- or LPS-stimulated macrophages.
Surface-enhanced laser desorption/ionization time-of-flight mass-
spectrometry demonstrated time-dependent formation of A-
containing peptides after platelet phagocytosis, which could be inhib-
ited by indomethacin. In conclusion, these results point to the
involvement of -secretase in macrophage activation following plate-
let phagocytosis.
Key Words: amyloid precursor protein, -amyloid peptide, induc-
ible nitric oxide synthase, macrophage activation, NSAID
(J Cardiovasc Pharmacol™ 2004;43:462–470)
Recently, we demonstrated the presence of amyloid- (A),which until then had only been studied in Alzheimer’s dis-
ease, in macrophages around microvessels in advanced human
atherosclerotic plaques.1 In these macrophages, the formation
of A was associated with the expression of inducible nitric
oxide synthase (iNOS). A source for A in atherosclerotic
plaques is blood platelets, which contain amyloid precursor
protein (APP) in the -granules. The platelets can enter ath-
erosclerotic plaques via leaky microvessels and are then
phagocytosed by macrophages,2 which subsequently trans-
form to foam cells.1 We proposed that during this process A-
like peptides are formed, which then activate the macrophage
as indicated by iNOS expression.1 This novel mechanism of
macrophage activation in atherosclerotic plaques may favor
plaque expansion and/or rupture. Indeed, the massive nitric ox-
ide (NO) release produced by iNOS has been reported to in-
duce apoptotic cell death of smooth muscle cells by enhancing
Fas-L/Fas interactions.3 In the atherosclerotic plaque, smooth
muscle cells are the only cells that are able to produce collagen
isoforms that contribute to the strength of the plaque.4 More-
over, activated macrophages can trigger the activation of ma-
trix metalloproteinases in the vascular interstitium,5 resulting
in degradation of the interstitial collagen fibers and decreased
strength of the fibrous cap of an atherosclerotic plaque.
The proteolytic enzymes responsible for A formation
in macrophages following platelet phagocytosis are not known
yet. In Alzheimer’s disease the insoluble A1-42 peptide is gen-
erated by the cleavage of its precursor APP, by two enzymes
designated - and -secretase. Recently, it was shown that in-
domethacin, ibuprofen, and sulindac sulfide directly affect the
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-secretase cleaving site of APP, thereby altering the amyloid
pathology in the brain.6 The latter effect results in a reduction
of the highly amyloidogenic A1-42 levels and an increase in
the less harmful A1-38 isoform. The interference with the
-secretase cleaving site is not seen with all NSAIDs and was
not dependent on cyclooxygenase (COX) inhibition. Indeed,
acetylsalicylic acid and naproxen do not affect the -secretase
cleaving site of APP. Since specific -secretase inhibitors are
not available, we used a series of NSAIDs to investigate the
participation of -secretase in macrophage activation and the
formation of A-like peptides following platelet phagocytosis.
METHODS
Cell Culture
The murine macrophage cell line J774A.1 (American
Type Culture Collection, Rockville, MD) was grown in RPMI
1640 medium supplemented with 10% fetal calf serum, 100
U/ml penicillin, 100 µg/ml streptomycin, 150 U/ml polymyxin
B, and 50 µg/ml gentamycin in a humidified 5% carbon
dioxide/95% air incubator at 37°C. All cell culture media and
supplements were from Invitrogen (Paisley, UK). For cell cul-
ture experiments 48 well plates (Costar, Cambridge, MA) or
culture slides (Beckton Dickinson Labware, Sunnyvale, CA)
were used. Cells (0.5 × 106/800 µL) were allowed to adhere at
37°C for 2 hours. Thereafter, cells were washed with warm
medium and the medium was replaced by Dulbecco Modified
Eagles Medium (DMEM) supplemented with 100 U/ml peni-
cillin, 100 µg/ml streptomycin, and 50 µg/ml gentamycin.
Human blood platelet concentrates were kindly pro-
vided by the blood transfusion center of the University Hospi-
tal of Antwerp (Belgium). These platelet concentrates had
been deleukocytized by filtration and contained only 1 to 2
white blood cells per 300,000 platelets. Platelets were washed
in warm PBS and resuspended in serum free Dulbecco Modi-
fied Eagles Medium (DMEM) supplemented with 100 U/ml
penicillin, 100 µg/ml streptomycin, and 50 µg/ml gentamycin.
J774 macrophages, primed with recombinant mouse
IFN (100 U/ml, Sigma), were incubated with washed human
platelets (108 per 0.5 × 106 macrophages)1 in the presence of an
NSAID or its solvent. After an incubation period of 18 hours,
the culture medium was removed from the macrophages, cen-
trifuged, and stored at −20°C for nitrite determination. To
study the specificity of NSAID treatment on the nitrite produc-
tion evoked by platelet phagocytosis, experiments using lipo-
polysaccharide (LPS) from Salmonella typhosa as an alterna-
tive stimulus for iNOS induction were performed as well.
Drugs
The following NSAIDs were examined (highest final
solvent concentration is indicated): indomethacin (Federa,
Brussels, Belgium, 0.5 mM TRIS pH 8.3), ibuprofen (Federa,
Brussels, Belgium, 0.5% ethanol), acetylsalicylic acid (Fe-
dera, Brussels, Belgium, 0.5% ethanol), naproxen (Federa,
Brussels, Belgium, 1% ethanol), meloxicam (Calbiochem, San
Diego, CA, 0.2% DMSO), and sulindac sulfide (Sigma, St
Louis, MO, 0.2% ethanol), the active metabolite of the prodrug
sulindac. They were dissolved at the start of every experiment
and the solutions were sterilized by filtration.
Nitrite Measurement
Nitric oxide synthase activity was assessed by measur-
ing nitrite, a stable NO metabolite, using the Griess reaction.7
Briefly, 200 µL culture medium was transferred to a 96-well
microtiter plate and mixed with 40 µL of 6.5 M HCl and 37.5
mM sulphanilic acid (1:1). After 10 minutes, 20 µL 12.5 mM
N-(1-naphtyl)-ethylene diamine dihydrochloride was added.
After 30 minutes at 37°C, the absorbance was read at 540 nm
using a Titertek Multiscan MCC/340 plate reader (Lab-
systems). Nitrite concentration was calculated from a standard
curve of sodium nitrite in culture medium.
Oil Red O Stain
To examine whether platelet engulfment by macro-
phages was altered by NSAIDs, co-incubations of macro-
phages and platelets were stained with oil red O8 after fixation
of the cells with 4% formaldehyde (10 minutes). Nuclei were
stained with hematoxylin.
Flow Cytometry
Phagocytosis of platelets by macrophages was also
evaluated by flow cytometry. J774 macrophages and washed
human platelets were incubated for 45 minutes with DMEM
supplemented with 5 µM of 5- and 6-([(4-chloromethyl) ben-
zoyl] amino) tetramethylrhodamine (Cell Tracker Orange,
Molecular probes) or 2.5 µM 5- chloromethylfluorescein diac-
etate (Cell Tracker Green, Molecular Probes), respectively.9
Thereafter, the media were refreshed, and the macrophages
were incubated with the platelets for 3.5 hours in the presence
or absence of the highest concentrations of these NSAIDs that
inhibited macrophage activation. This time point was based on
previous experiments on the evaluation of platelet phagocyto-
sis using confocal and electron microscopy.1 Flow cytometry
was performed using a FACSort (BD Biosciences, San Diego,
CA). Forward and side scatters were set to include cells but to
exclude debris. Green fluorescent-free platelets were moni-
tored in the FL 1 channel, whereas orange fluorescent mac-
rophages were measured in the FL 3 channel. Data were
analyzed using CellQuestPro software (BD Biosciences).
Phagocytosis (per cent) was calculated as the (number of cells
containing cell tracker green and orange / total number of cells
containing cell tracker orange) × 100.
Cyclooxygenase Inhibition and Determination
of Prostaglandin E2
To document COX inhibition, we tested all NSAIDs on
their ability to inhibit arachidonic acid-induced blood platelet
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aggregation. Blood samples (9 mL) were obtained from a
cannulated carotid artery of pentobarbitone (30 mg/kg)-
anesthetized New Zealand White rabbits and collected on tri-
sodiumcitrate (1 mL; 3.8%). Platelet-rich plasma was prepared
by centrifugation (10 minutes, 200 g). The samples were ex-
posed to 330 µM arachidonic acid after 3 minutes incubation in
the presence or absence of the NSAIDs in a Chronolog dual
channel aggregometer (37°C, 900 rpm).9 The maximum in-
crease in light transmission after the addition of arachidonic
acid was measured.
PGE2 was measured in the culture medium by radio-
immunoassay. Dose interpolation was done with a four-
parameter logistic function using the IBM-PC RIA data
reduction package provided by M.L. Jaffe (Silver Spring,
MD).10
Surface-Enhanced Laser Desorption/Ionization
Time-of-Flight (SELDI-TOF) Mass Spectrometry
Analysis of APP fragments in cell lysates of macro-
phages, platelets, and macrophages co-incubated with platelets
for 3, 6, or 18 hours with or without indomethacin was per-
formed by SELDI-TOF mass spectrometry using the Protein-
Chip system (PS20, protein chip array, Ciphergen Biosystems
Inc., Fremont, CA). Cells were lysed for 30 minutes in 50 mM
TRIS buffer containing 250 mM NaCl, 5 mM EDTA, 0.1%
(vol/vol) Triton X 100, 1 mM dithiothreitol, 1 mM NaF, 10
mM -glycerophosphate, 0.1 mM Na3VO4, and 0.1 mM para-
methylsulphonylfluoride.
The chip arrays were incubated overnight at 4°C with the
antibody (6E10 or IgG) to allow coupling. 6E10 is an antibody
specific for the 17 N-terminal amino acids of -amyloid pep-
tides (672–688 of the full-length APP sequence). IgG antibody
coating was used as a control to discriminate between specific
and aspecific peptide binding to the protein chip. The samples
were diluted and 20 µg total protein was spotted on the 6E10 or
IgG antibody-coated chips. After 4 hours, non-bound peptides
were removed by extensive washing with PBS and PBS con-
taining 0.5% Triton X 100. The arrays were rinsed several
times with a 1.0-mM HEPES buffer, and allowed to air dry.
Thereafter, 1 µL of a 20% saturated solution of -cyano-4-
hydroxycinnamic acid in 0.5% (vol/vol) trifluoroacetic acid:
50% (vol/vol) acetonitrile was applied to each spot. Mass spec-
trometric analysis was performed by averaging a minimum of
100 laser shots in a Ciphergen SELDI Protein Biology system
II, with a linear time-of-flight mass analyzer (mass accuracy:
0.1%).11–14
Statistical Analysis
Nitrite values were compared by using analysis of vari-
ance (ANOVA). A P value less than 0.05 was considered to be
significant. All data are represented as mean ± SEM.
RESULTS
Effect of NSAIDs on Nitrite Production
Incubation of IFN-primed J774 macrophages with
washed human platelets or LPS resulted in nitrite production
by the macrophages. The extent of the nitrite production was
comparable for both stimuli. Addition of indomethacin, ibu-
profen, meloxicam, or sulindac sulfide to the culture medium
concentration-dependently reduced nitrite production by mac-
rophages evoked by platelet phagocytosis (Fig. 1, A–D),
whereas acetylsalicylic acid or naproxen were without such an
inhibitory effect (Fig. 1, E and F). As compared with indo-
methacin, sulindac sulfide, and meloxicam, the effect of ibu-
profen was less pronounced. When macrophages were stimu-
lated with LPS, nitrite production was not affected by any
NSAID (Fig. 1, A–F).
Effect of NSAIDs on Platelet Aggregation and
PGE2 Production
The production of PGE2 by macrophages stimulated
with either platelets or LPS was significantly reduced in the
presence of all NSAIDs (results not shown). Moreover, all
NSAIDs inhibited arachidonic acid-induced platelet aggrega-
tion. After 3 minutes of exposure the percentage inhibition
was: indomethacin (10, 50, 100 µM), 97% for all concentra-
tions, ibuprofen (100, 200, 300 µM), 9%, 92%, and 96%,
meloxicam (10, 30, 50 µM), 50%, 97%, and 97%, acetylsali-
cylic acid (50, 250, 500 µM), 13%, 96%, and 96% and
naproxen (75, 150 µM), 12% and 97%. Sulindac sulfide was
less effective as platelet inhibitor: 1 µM reduced the platelet
aggregation with 3% and 10 µM with 18%.
Platelet Phagocytosis and Foam Cell Formation
Flow cytometry revealed that after 3.5 hours platelet
phagocytosis was not altered in the presence of 100 µM indo-
methacin, 500 µM ibuprofen, 10 µM sulindac sulfide, and 50
µM meloxicam (Fig. 2).
Lipid accumulation in the macrophages as a result of
platelet phagocytosis was not changed in the presence of 100
µM indomethacin, indicating that platelet phagocytosis was
not altered by this NSAID (Fig. 2). Similarly, the other
NSAIDs did not alter platelet phagocytosis (not shown).
Detection of APP-Fragments by SELDI-TOF
Mass Spectrometry
The mass spectrum of the lysate of macrophages incu-
bated for 3 hours with human blood platelets did not show
peaks corresponding to A1-40 or A1-42 fragments (Fig. 3).
However, in the lysate of macrophages incubated with blood
platelets for 6 or 18 hours, two peaks at m/z 6277.5 and m/z
6541.5 were detected, which correspond to the [M + H]+ peaks
of proteins with a molecular mass of 6276.5 Da and 6540.5 Da,
respectively. The intensity of these peaks increased with an
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FIGURE 1. Legend on facing page.
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increasing incubation time of platelets and macrophages (Fig.
3), which paralleled nitrite production (0.49 ± 0.03 µM after 3
hours, 0.80 ± 0.07 µM after 6 hours and 6.8 ± 0.2 µM after 18
hours). For the 6276.5 Da protein, six different APP-derived
peptides are theoretically possible within a mass range of ± 5
Da (Table 1). The peak at m/z 6541.5 was not detected in every
experiment and will not be considered in the present study.
When macrophages were incubated with platelets in the
presence of indomethacin for 18 hours, [M + H]+ peaks at m/z
6277.5 and 6541.5 disappeared completely. This was accom-
panied by peaks in the mass ranges m/z 5000–6000 and m/z
7000–8000 (Fig. 4). In all cases, a standard mixture gave the
expected profile with [M + H]+ peaks at m/z 1953.5 (A1-16,
not shown), 4343.5 (A1-40), and 4527.6 (A1-42).
DISCUSSION
Recently, it was demonstrated that in neuronal cells a
subset of NSAIDs including indomethacin, ibuprofen, and su-
lindac sulfide alter the -secretase cleaving site of APP.6 As a
result, the formation of A1-42, the most toxic form of A, was
reduced in favor for the less toxic A1-38.
6 Indeed, it has been
suggested6 that this interference with the -secretase cleaving
site of APP may explain the benefit of some NSAIDs seen in
epidemiological15–17 and clinical studies18–20 of Alzheimer’s
disease. Since specific inhibitors of -secretase are currently
not available or cytotoxic (unpublished observations), we in-
vestigated a series of NSAIDs to test whether -secretase is
involved in platelet-induced macrophage activation. These
NSAIDs were merely selected as pharmacological tools to un-
FIGURE 1. Effect of indomethacin (A, Platelets: n = 6, LPS: n = 2–4), ibuprofen (B, n = 4), sulindac sulfide (C, n = 3), meloxicam
(D, n = 3), acetylsalicylic acid (E, PLT: n = 6, LPS: n = 2), and naproxen (F, PLT: n = 9, LPS: n = 3) on nitrite production by
macrophages after incubation with platelets or LPS for 18 hours. Indomethacin, ibuprofen, sulindac sulfide, and meloxicam
reduced platelet-induced nitrite production by macrophages concentration-dependently but did not affect LPS-induced nitrite
production. Acetylsalicylic acid and naproxen did not alter nitrite production by macrophages after incubation with either blood
platelets or LPS. Open bars: solvent control, hatched bars: NSAID-treated; *P < 0.05, **P < 0.01, ***P < 0.001 versus solvent
control.
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ravel the mechanisms of macrophage activation after platelet
phagocytosis.
The present data confirm that platelets are phagocytosed
by macrophages (flow cytometry), that the macrophages be-
come activated (nitrite production) and transform to foam cells
(oil red O). Foam cell formation can result from other mecha-
nisms than platelet phagocytosis. Since we used serum-free
medium, endocytosis of lipid droplets can be excluded. En-
gulfment of LDL or modified LDL bound to the platelets is
possible but seems to be less important because we used
washed human platelets. With flow cytometry, we could dem-
onstrate that platelets are indeed phagocytosed by macro-
phages, confirming previous results.1
Subsequently, our results clearly showed a reduced ni-
trite production when macrophages were incubated with plate-
lets in the presence of indomethacin, ibuprofen, sulindac sul-
fide, and meloxicam as compared with the controls.
Importantly, the concentrations of the NSAIDs used in the
present study did not affect LPS-induced nitrite production,
confirming previous reports.21–23 The latter finding indicates
that the inhibitory activity of NSAIDs on macrophage activa-
tion following platelet phagocytosis was not due to interfer-
ence with the cell signaling pathways essential for iNOS in-
duction or with the activity of iNOS. Indeed, Aeberhard et al22
showed that only extremely high concentrations of NSAIDs,
exceeding those of the present study, inhibit iNOS activity in
LPS-stimulated macrophages. Moreover, the inhibitory activ-
ity of indomethacin, ibuprofen, sulindac sulfide, and meloxi-
cam on macrophage activation evoked by platelet ingestion
was not due to reduced platelet phagocytosis or processing.
The different compounds did not inhibit the early platelet up-
take as studied by flow cytometry, nor did they suppress the
accumulation of platelet-derived lipid droplets inasmuch as oil
red O staining of NSAID-treated macrophages did not differ
from that of untreated macrophages. Furthermore, these ex-
periments revealed no differences in platelet uptake between
NSAID-treated and control macrophages.
Both PGE2 measurements in the supernatant and arachi-
donic acid-induced blood platelet aggregation assays showed
that all NSAIDs inhibited COX, confirming their activity and
excluding possible degradation of the drugs. However, inhibi-
tion of macrophage activation by the NSAIDs was not due to
COX-inhibition. Except for ibuprofen, the concentrations of
the NSAIDs required to affect the macrophage activation after
FIGURE 2. Effect of NSAIDs on platelet phagocytosis. Flow cytometric evaluation of platelet phagocytosis by macrophages with
or without indomethacin 100 µM (Indo, A), ibuprofen 500 µM (Ibu, B), sulindac sulfide 10 µM (Sul, C), and meloxicam 50 µM
(Mel, D). Results are presented as percentage of the population that has engulfed platelets. Oil red O stain of control macrophages
(E) and macrophages incubated with human platelets in the presence (F) or absence (G) of 100 µM indomethacin. Lipid
accumulation in the macrophages (arrowheads) was not changed in the presence of indomethacin further indicating that platelet
phagocytosis was not altered by this NSAID. Bar = 10 µm.
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platelet ingestion were higher than those necessary for COX
inhibition. Secondly, sulindac sulfide, the least effective COX
inhibitor, was even the most active inhibitor of macrophage
activation following platelet phagocytosis. More importantly,
although acetylsalicylic acid and naproxen inhibited COX,
they did not alter nitrite production of macrophages induced by
platelet phagocytosis. Indeed, the latter NSAIDs do not affect
the -secretase cleaving site of APP.6 Taken together, these
findings suggest that the effect of some NSAIDs on nitrite for-
mation could be due to interference with the -secretase cleav-
ing site of APP, thereby reducing the formation of A-like
peptides.
Previously, Ogawa et al24 reported that A1-40 could
stimulate nitrite production in IFN-primed J774 macro-
phages. They further showed that indomethacin and ibuprofen
inhibited the A-effect and proposed that the inhibitory effects
of these NSAIDs on iNOS expression were mediated via per-
oxisome proliferator-activated receptor- (PPAR-). Unfortu-
nately, we were unable to reproduce these experiments. We
encountered a great batch-to-batch variability in the response
to A1-40 as well as A1-42 and the nitrite production of IFN-
TABLE 1. Different Theoretically Possible APP-Derived
Peptides With a Molecular Mass of 6276.5 5 Da That














6276.5 6278.9 2.4 56 635–690
6271.9 −4.6 56 640–695
6273.9 −2.6 57 644–700
6273.9 −2.6 57 648–704
6275.1 −1.4 58 656–713
6273.3 −3.2 57 672–728
All peptides contain the complete epitope of the 6E10 antibody (17 N-
terminal amino acids of A (ie amino-acids 672–688 of full length APP)).
Peptides are ranked according to their sequence in full-length APP, with their
theoretical mass, the difference between the theoretical mass and the measured
mass and the number of amino acids. Cleaving sites of - or -secretase are
marked in bold.
FIGURE 3. SELDI-TOF mass spectra of the lysate of co-incubations of macrophages and blood platelets (M + PLT) (3 hours, 6 hours,
and 18 hours). When macrophages were incubated with blood platelets, an A-like fragment was time-dependently formed with
a molecular mass of 6276.5 Da. A standard mixture of A1-16, A1-40, and A1-42 gave the expected profile with [M + H]
+ peaks
at m/z 1953.5 (not shown), 4343.5, and 4527.6, respectively.
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primed macrophages after stimulation with either peptide was
too low to study the effect of inhibitors.1 Since Ogawa et al24
did not investigate whether the inhibition by the NSAIDs was
specific for A1-40 by including an alternative stimulus, such
as LPS, their experiments cannot be compared with the present
study in which we used platelets as a stimulus. Furthermore,
the active concentrations of indomethacin and ibuprofen were
even higher than in the present study and could have interfered
directly with the activity of iNOS, as reported by Aeberhard et
al.22 Since NSAIDs used in the present study did not interfere
with the LPS-induced expression or activity of iNOS, it seems
less likely that the concentrations used in the present study in-
terfered with PPAR- nuclear receptors as proposed by Ogawa
et al24. However, it cannot be excluded that some of their in-
hibitory effects were due to interference with iNOS- inducing
pathways distal from A-production.
Subsequently, SELDI-TOF mass spectrometry was used
to substantiate the -secretase involvement. This technique
demonstrated that incubation of macrophages with platelets re-
sulted in a time-dependent formation of a peptide with a mo-
lecular mass of 6276.5 Da, containing an A-like domain. The
properties and the importance of this peptide are still unclear.
Only its molecular mass is known and the fact that it contains
the epitope recognized by the 6E10 antibody. Six theoretically
possible A-like peptides with a molecular mass of 6276.5 ± 5
Da remained after excluding peptides without the epitope of
the 6E10 antibody on the SELDI chip. Two of these candidates
deserve further consideration. The first one, which has a mass
of 6275.1 Da, is 58 amino acids long and contains the complete
A1-42 sequence (ie, amino acids 672–713 of full-length APP)
at its C-terminal site, ending just at the -secretase cleaving
site (Table 1). The difference between the theoretical mass and
the measured mass was the lowest for this peptide as compared
with the other five candidates. Another interesting candidate
has a mass of 6273.3 Da, is 57 amino acids long and contains
the complete A1-42 sequence at its N-terminal site, starting
with the -secretase cleaving site (Table 1). The exact identity
of the A-like peptide with a mass of 6276.5 ± 5 Da formed
during platelet phagocytosis by macrophages remains to be es-
tablished. Also the importance of the presence of the complete
A1-42 sequence in this A-like peptide remains to be deter-
mined, since A1-42 itself had only a limited effect on the ac-
FIGURE 4. SELDI-TOF mass spectra of the lysate of co-incubations of J774 macrophages and blood platelets (M + PLT) for 18 hours
in the presence (M + PLT + Indo 100 µM) or absence (M + PLT + TRIS) of 100 µM indomethacin. Incubation of macrophages and
platelets for 18 hours in the presence of indomethacin inhibited the formation of the [M + H]+ peak at m/z 6277.5. The standard,
a mixture of A1-16, A1-40, and A1-42, gave the expected profile with [M + H]
+ peaks at m/z 1953.5 (not shown), 4343.5, and
4527.6, respectively. The IgG control was negative.
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tivation of both J774 macrophages, as discussed before, and
microglia cells.25 Nevertheless, the present study showed that
addition of indomethacin to the co-incubations of platelets and
macrophages inhibited the formation of this peptide, as well as
nitrite production. This strongly suggests that the A-like pep-
tide with a mass 6276.5 ± 5 Da participates in macrophage
activation following platelet phagocytosis.
In summary, our results demonstrate that NSAIDs
known to alter the -secretase cleaving site of APP, as well as
meloxicam, reduced macrophage activation following platelet
phagocytosis, but not after LPS stimulation. Furthermore,
NSAIDs like acetylsalicylic acid and naproxen, which do not
affect -secretase cleavage were also without effect on macro-
phage activation after platelet ingestion. This indicates that the
reduced macrophage activation is independent of COX-
inhibition and points to an effect on -secretase. The inhibition
of the formation of A-related peptides by indomethacin, mea-
sured by SELDI-TOF, gives further support to the idea that
NSAIDs act via interference with a -secretase-related path-
way, although further research is necessary to identify the pep-
tide(s). Finally, our findings indicate that the novel platelet-
induced pathway of macrophage activation can be treated in a
pharmacological way. This may open new perspectives for the
development of specific drugs for intervention in the complex
matter of plaque physiology.5
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